{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.78","value":"8.45"},{"groupId":"OG001","spread":"1.76","value":"42.7"},{"groupId":"OG002","spread":"26.6","value":"142"},{"groupId":"OG003","spread":"70.7","value":"144"},{"groupId":"OG004","spread":"0.111","value":"0.383"},{"groupId":"OG005","spread":"1.41","value":"1.69"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"description":"maximum observed concentration (Cmax)","dispersionType":"Standard Deviation","groups":[{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG000","title":"Cohort 1: N-803 - IV 1 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG001","title":"Cohort 2: N-803 - IV 3 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG002","title":"Cohort 3: N-803 - IV 6 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG003","title":"Cohort 4: N-803 - IV 10 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG004","title":"Cohort 5: N-803 - SQ 10 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG005","title":"Cohort 6: N-803 - SQ 15 ug/kg"}],"paramType":"MEAN","populationDescription":"Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects","reportingStatus":"POSTED","timeFrame":"PK timepoint up to 72 hours +/- 6 hours","title":"Characterization of the Pharmacokinetic Profile - Maximum Observed Concentration (Cmax)","type":"SECONDARY","unitOfMeasure":"ng/mL"}